Immunome, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Directors make important company decisions, so knowing who runs the company and how they were chosen matters to investors.
Quarterly earnings show whether the company is making money and progressing toward its goals.
Independent auditors verify company finances are accurate, protecting investor confidence and trust.
Annual earnings reveal how profitable the company is and whether it achieved its goals for the year.
This vote shows if shareholders think company leaders are paid fairly relative to company performance.
Stocky reads Immunome, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Immunome, Inc.'s most recent tracked filing was a 8-K on 12 Jun 2026: Stockholders elect three directors to three-year terms.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.